in the absence of a submission from the holder of the marketing authorisation:
dupilumab (Dupixent®) is not recommended for use within NHSScotland.
Indication under review: treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice234KB (PDF)
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2682
- Indication:
For treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
- Pharmaceutical company
- Sanofi
- BNF chapter
- Gastro-intestinal system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 June 2024